Skip to main content
17/05/2024 - 11:00

PharmAust receives FDA approval

17/05/2024 - 11:00

Bookmark

Save articles for future reference.

Shares in Claremont-based PharmAust rose 5 per cent early on Friday morning, following news the company had received orphan drug designation for both monepantel and the treatment of motor neurone disease and amyotrophic lateral sclerosis.

X

To read our articles you will need to either login or subscribe.